Last reviewed · How we verify
CC10004
At a glance
| Generic name | CC10004 |
|---|---|
| Also known as | Apremilast |
| Sponsor | Amgen |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Human Laboratory Study of Apremilast for Alcohol Use Disorder (PHASE2)
- I-SPY COVID-19 TRIAL: An Adaptive Platform Trial for Critically Ill Patients (PHASE2)
- Apremilast Pediatric Study in Children With Active Juvenile Psoriatic Arthritis (PHASE3)
- Apremilast for Alcohol Use Disorder Treatment in Women and Men (PHASE1)
- Dose-response Study of Apremilast in Women and Men With Alcohol Use Disorder (PHASE2)
- A Study to Investigate Efficacy and Safety of Apremilast 30 mg Twice Daily (BID) in Chinese Participants With Moderate to Severe Plaque-type Psoriasis (PsO) (PHASE3)
- A Long-term Extension Study of Apremilast (CC-10004) in Pediatric Subjects From 6 Through 17 Years of Age With Moderate to Severe Plaque Psoriasis (PHASE3)
- A Study to Assess the Efficacy and Safety of Apremilast in Japanese Pediatric Participants With Moderate to Severe Plaque Psoriasis (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- CC10004 CI brief — competitive landscape report
- CC10004 updates RSS · CI watch RSS
- Amgen portfolio CI